The role of ultrasound contrast agents in gene therapy

Applied Radiology

Volumn 33, Issue SUPPL., 2004, Pages 126-135

  Howard, Candace M ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; BETA GLOBULIN; CATION; CISPLATIN; CONTRAST MEDIUM; CYTARABINE; DNA; LENTIVIRUS VECTOR; LIDOCAINE; LIPID; NAKED DNA; ORNITHINE CARBAMOYLTRANSFERASE; PARVOVIRUS VECTOR; PHOTOFRIN; PLASMID VECTOR; RETROVIRUS VECTOR; THYMIDINE KINASE;

BETA THALASSEMIA; CELL ADHESION; CELL MEMBRANE PERMEABILITY; CELL SPECIFICITY; CONTRAST ENHANCEMENT; CREATIVITY; DISEASE MARKER; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DRUG RELEASE; ECHOGRAPHY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; IMAGING SYSTEM; IONIZING RADIATION; MOLECULAR BIOLOGY; NON INVASIVE MEASUREMENT; NONVIRAL GENE DELIVERY SYSTEM; PHYSICAL PHENOMENA; REVIEW; SHOCK WAVE; TIME; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

EID: 7444244367     PISSN: 01609963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Sullenger BA. Targeted genetic repair: An emerging approach to genetic therapy. J Clin Invest. 2003;112: 310-311.
2. Russell SJ, Peng,KW. Primer on medical genomics. Part X: Gene therapy. Mayo Clin Proc. 2003;78: 1370-1383.
3. Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol 2003;2:117-122.
4. Crystal RG. The Gordon Wilson Lecture. In vivo gene therapy: A strategy to use human genes as therapeutics. Trans Am Clin Climatol Assoc. 1994;106:87-99.
5. McMahon JM, Wells KE, Bamfo JE, et al. Inflammatory responses following direct injection of plasmid DNA into skeletal muscle. Gene Ther. 1998;5:1283-1290.
6. Crystal RG. Transfer of genes to humans: Early lessons and obstacles to success. Science. 1995;270: 404-410.
7. Crystal RG. The gene as the drug. Nat Med. 1995; 1:15-17.
8. Varmus HE. Form and function of retroviral proviruses. Science. 1982;216:812-820.
9. Claudio PP, Howard CM, Pacilio C, et al. Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res. 2000; 60:372-382.
10. Claudio PP, Stiegler P, Howard CM, et al. RB2/p130 gene-enhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo. Cancer Res. 2001; 61:462-468.
11. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol. 1990; 10:4239-4242.
12. Sokol DL, Gewirtz AM. Gene therapy: Basic concepts and recent advances. Crit Rev Eukaryot Gene Expr. 1996;6:29-57.
13. Kohn DB, Anderson WF, Blaese RM. Gene therapy for genetic diseases. Cancer Invest. 1989;7:179-192.
14. Gilboa E. Retroviral gene transfer: Applications to human therapy. Prog Clin Biol Res. 1990;352:301-311.
15. Cournoyer D, Caskey CT. Gene therapy of the immune system. Annu Rev Immunol. 1993;11:297-329.
16. Miller AD. Retrovirus packaging cells. Hum Gene Ther. 1990;1:5-14.
17. Mulligan RC. The basic science of gene therapy. Science 1993;260:926-932.
18. Soneoka Y, Cannon PM, Ramsdale EE, et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 1995;23:628-633.
19. Burns JC, Friedmann T, Driever W, et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA. 1993;90:8033-8037.
20. Quinonez R, Sutton RE. Lentiviral vectors for gene delivery into cells. DNA Cell Biol. 2002;21:937-951.
21. Follenzi A, Battaglia M, Lombardo A, et al. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood. 2004;103:3700-3709.
22. Follenzi A, Sabatino G, Lombardo A, et al. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther. 2002;13:243-260.
23. Fleury S, Simeoni E, Zuppinger C, et al. Multiply attenuated, self-inactivating lentiviral vectors efficiently deliver and express genes for extended periods of time in adult rat cardiomyocyte in vivo. Circulation. 2003; 107:2375-2382.
24. Roy I. Ethical considerations in the use of lentiviral vectors for genetic transfer. Somat Cell Mol Genet. 2001;26:175-191.
25. Pannell D, Ellis J. Silencing of gene expression: implications for design of retrovirus vectors. Rev Med Virol. 2001;11:205-217.
26. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255-256.
27. Zabner J, Couture LA, Gregory RJ, et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell. 1993;75:207-216.
28. Hyde SC, Gill DR, Higgins CF, et al. Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature. 1993;362:250-255.
29. Rosenfeld MA, Siegfried W, Yoshimura K, et al. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science. 1991;252:431-434.
30. Jones N, Shenk T. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell. 1979;17:683-689.
31. Nakai H, Montini E, Fuess S, et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet. 2003;34:297-302.
32. Duverger V, Sartorius U, Klein-Bauemschmitt P, et al. Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2. Int J Cancer. 2002;97:706-712.
33. Marshall E. Scientific misconduct. How prevalent is fraud? That's a million-dollar question. Science. 2000; 290:1662-1663.
34. Marshall E. Medical ethics. Moratorium urged on germ line gene therapy. Science. 2000;289:2023.
35. Marshall E. Biomedical ethics. Penn report, agency heads home in on clinical research. Science. 2000; 288:1558-1559.
36. Marshall E. Biomedical ethics. HHS plans to overhaul clinical research rules. Science. 2000;288: 1315-1316.
37. Marshall E. Gene therapy's web of corporate connections. Science. 2000;288:954-955.
38. Marshall E. FDA halts all gene therapy trials at Penn. Science. 2000;287:565,567.
39. Hacein-Bey S, Yates F, de Villartay JP, et al. Gene therapy of severe combined immunodeficiencies: From mice to humans. Neth J Med. 2002;60:299-301.
40. Claudio PP, Fratta L, Farina F, et al. Adenoviral RB2/p130 gene transfer inhibits smooth muscle cell proliferation and prevents restenosis after angioplasty. Circ Res. 1999;85:1032-1039.
41. Varenne O, Sinnaeve P, Gillijns H, et al. Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteries. Hum Gene Ther. 2000;11:1329-1339.
42. Gramiak R, Shah PM. Echocardiography of the aortic root. Invest Radiol. 1968;3:356-366.
43. Goldberg BB, Liu JB, Forsberg F. Ultrasound contrast agents: A review. Ultrasound Med Biol. 1994;20: 319-333.
44. Nanda NC, Carstensen C. Echo-enhancing agents safety. In: Nanda NC, Schlief R, Goldberg BB, eds. Advances in Echo Imaging Using Contrast Enhancers. Kluwer: Dordrecht, Netherlands; 1997:115-131.
45. Kaul S. Myocardial contrast echocardiography. Curr Probl Cardiol. 1997;22:549-635.
46. Mayer S, Graybum PA. Myocardial contrast agents: Recent advances and future directions. Prog Cardiovasc Dis. 2001; 44:33-44.
47. Porter TR, Xie F, Li S. Differences in myocardial contrast produced with transient response imaging when using intravenous microbubbles containing gases of different molecular weight. Echocardiography. 1997; 14:441-446.
48. Porter TR, Xie F. Visually discernible myocardial echocardiographic contrast after intravenous injection of sonicated dextrose albumin microbubbles containing high molecular weight, less soluble gases. J Am Coll Cardiol. 1995;25:509-515.
49. Dayton P, Klibanov A, Brandenburger G, et al. Acoustic radiation force in vivo: A mechanism to assist targeting of microbubbles. Ultrasound Med Biol. 1999;25:1195-1201.
50. Dayton PA, Chomas, JE, Lum AF, et al. Optical and acoustical dynamics of microbubble contrast agents inside neutrophils. Biophys J. 2001;80:1547-1556.
51. Lindner JR, Dayton PA, Coggins MP, et al. Noninvasive imaging of inflammation by ultrasound detection of phagocytosed microbubbles. Circulation. 2000; 102:531-538.
52. Skyba DM, Camarano G, Goodman NC, et al. Hemodynamic characteristics, myocardial kinetics and microvascular rheology of FS-069, a second-generation echocardiographic contrast agent capable of producing myocardial opacification from a venous injection. J Am Coll Cardiol. 1996;28:1292-1300.
53. Keller MW, Segal SS, Kaul S, et al. The behavior of sonicated albumin microbubbles within the microcirculation: A basis for their use during myocardial contrast echocardiography. Circ Res. 1989;65:458-467.
54. Jayaweera AR, Edwards N, Glasheen WP, et al. In vivo myocardial kinetics of air-filled albumin microbubbles during myocardial contrast echocardiography. Comparison with radiolabeled red blood cells. Circ Res. 1994;74:1157-1165.
55. Levine RA, Teichholz LE, Goldman ME, et al. Microbubbles have intracardiac velocities similar to those of red blood cells. J Am Coll Cardiol. 1984;3:28-33.
56. Merritt CR. Technology update. Radiol Clin North Am. 2001;39:385-397.
57. Wei K, Jayaweera AR, Firoozan S, et al. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation. 1998;97:473-483.
58. Park JH, Nazarian LN, Halpern EJ, et al. Comparison of unenhanced and contrast-enhanced spiral CT for assessing interval change in patients with colorectal liver metastases. Acad Radiol. 2001;8:698-704.
59. Nazarian LN, Park JH, Halpern EJ, et al. Size of colorectal liver metastases at abdominal CT: Comparison of precontrast and postcontrast studies. Radiology. 1999;213:825-830.
60. Albrecht T, Hoffmann CW, Schmitz SA, et al. Phase-inversion sonography during the liver-specific late phase of contrast enhancement: Improved detection of liver metastases. AJR Am J Roentgenol. 2001; 176:1191-1198.
61. Harvey CJ, Blomley MJ, Eckersley RJ, et al. Pulse-inversion mode imaging of liver specific microbubbles: Improved detection of subcentimetre metastases. Lancet. 2000;355:807-808.
62. Blomley MJ, Albrecht T, Cosgrove DO, et al. Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508A: Early experience. Radiology. 1999;210:409-416.
63. Burns PN. Harmonic imaging with ultrasound contrast agents. Clin Radiol. 1996;51(suppl 1):50-55.
64. Forsberg F, Dicker AP, Thakur ML, et al. Comparing contrast-enhanced ultrasound to immunohistochemical markers of angiogenesis in a human melanoma xenograft model: Preliminary results. Ultrasound Med Biol. 2002;28:445-451.
65. Merritt CR. Imaging the results of antiangiogenesis therapy. Acad Radiol. 2001;8:119-120.
66. Skyba DM, Price RJ, Linka AZ, et al. Direct in vivo visualization of intravascular destruction of microbubbles by ultrasound and its local effects on tissue. Circulation. 1998;98:290-293.
67. Price RJ, Skyba DM, Kaul S, et al. Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound. Circulation. 1998;98: 1264-1267.
68. Unger EC, Hersh E, Vannan M, et al. Local drug and gene delivery through microbubbles. Prog Cardiovasc Dis. 2001;44:45-54.
69. Tata DB, Dunn F, Tindall DJ. Selective clinical ultrasound signals mediate differential gene transfer and expression in two human prostate cancer cell lines: LnCap and PC-3. Biochem Biophys Res Commun. 1997;234:64-67.
70. Fechheimer,M, Boylan JF, Parker S, et al. Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading. Proc Natl Acad Sci USA. 1987;84:8463-8467.
71. Anwer K, Kao G, Proctor B, et al. Ultrasound enhancement of cationic lipid-mediated gene transfer to primary tumors following systemic administration. Gene Ther. 2000;7:1833-1839.
72. Nahman NS, Sferra TJ, Kronenberger J, et al. Microsphere-adenoviral complexes target and transduce the glomerulus in vivo. Kidney Int. 2000;58: 1500-1510.
73. Lu QL, Liang HD, Partridge T, et al. Microbubble ultrasound improves the efficiency of gene transduction in skeletal muscle in vivo with reduced tissue damage. Gene Ther. 2003;10:396-405.
74. Taniyama Y, Tachibana K, Hiraoka K, et al. Development of safe and efficient novel nonviral gene transfer using ultrasound: Enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther. 2002;9:372-380.
75. Bekeredjian R, Chen S, Frenkel PA, et al. Ultrasound-targeted microbubble destruction can repeatedly direct highly specific plasmid expression to the heart. Circulation. 2003;108:1022-1026.
76. Unger EC, Matsunaga TO, McCreery T, et al. Therapeutic applications of microbubbles. Eur J Radiol. 2002;42:160-168.
77. Shohet RV, Chen S, Zhou YT, et al. Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation. 2000; 101:2554-2556.
78. Beeri R, Guerrero JL, Supple G, et al. New efficient catheter-based system for myocardial gene delivery. Circulation. 2002;106:1756-1759.
79. Chen S, Shohet RV, Bekeredjian R, et al. Optimization of ultrasound parameters for cardiac gene delivery of adenoviral or plasmid deoxyribonucleic acid by ultrasound-targeted microbubble destruction. J Am Coll Cardiol. 2003;42:301-308.
80. Lindner JR. Evolving applications for contrast ultrasound. Am J Cardiol. 2002;90(10A):72J-80J.
81. Lindner JR. Assessment of inflammation with contrast ultrasound. Prog Cardiovasc Dis. 2001;44: 111-120.
82. Lindner JR, Song J, Christiansen J, et al. Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation. 2001;104:2107-2112.
83. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
84. Unger EC, McCreery TP, Sweitzer RH, et al. In vitro studies of a new thrombus-specific ultrasound contrast agent. Am J Cardiol. 1998;81(12A):58G-61G.
85. Schumann PA, Christiansen JP, Quigley RM, et al. Targeted-microbubble binding selectively to GPIIb IIIa receptors of platelet thrombi. Invest Radiol. 2002; 37:587-593.
86. Tachibana K, Tachibana S. Albumin microbubble echo-contrast material as an enhancer for ultrasound accelerated thrombolysis. Circulation. 1995;92:1148-1150.
87. Francis,CW, Onundarson PT, Carstensen EL, et al. Enhancement of fibrinolysis in vitro by ultrasound. J Clin Invest. 1992;90:2063-2068.